Copper

Cu(ATSM) Copper Drug Shows Preclinical Alzheimer's Breakthrough, Poised for Fast-Track Clinical Development

Monash University's preclinical research reveals Cu(ATSM), a copper-based compound, significantly reduces toxic amyloid-beta proteins by 42% and improves spatial memory by 44% in Alzheimer's models. This breakthrough, published June 16, 2026, is poised for accelerated clinical development, leveraging existing human safety data from Parkinson's and ALS trials. This offers a fast-track opportunity for pharmaceutical companies seeking novel neurovascular-targeting Alzheimer's therapies, impacting future procurement and market strategies.